Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hylube Ultra
- Development stage
- Unknown
- Lead developer
- Jainson Biotech
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Hylube Ultra is an ophthalmic lubricant eye drop developed and marketed by Jainson Biotech. It is a fixed-dose combination of polyethylene glycol (0.4% w/v) and propylene glycol (0.3% w/v). The formulation is approved for the temporary relief of burning, irritation, and discomfort caused by dry eyes. Both active ingredients function as demulcents and lubricants that mimic natural tears, helping to restore moisture to the ocular surface, stabilize the tear film, and protect the eyes from environmental irritants.
- Brand names
- Hylube Ultra
- Other names
- polyethylene glycol + propylene glycol
Beyond the preview
Go deeper on Hylube Ultra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hylube Ultra.